Brean Murray Carret & Co. Starts Incyte (INCY) at Buy, Price Target $22
Tweet Send to a FriendGet Alerts INCY Hot Sheet
Price: $23.04 -0.56%
Rating Summary:
10 Buy, 4 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
10 Buy, 4 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade INCY Now!
Brean Murray Carret & Co. initiates coverage on Incyte (NASDAQ: INCY) with a Buy rating and a price target of $22. The firm placed ESP estimates of -$0.32 and -$0.63 for FY10 and FY11.
The firm believes that approval from the FDA and EMEA for the drug INCB18424 is very likely. This will be the first approved drug for Myeloproliferative diseases and the next competitor is still two years behind nor does it treat many of the problems that characterize myelofibrosis (MF) and polycythemia (PV). There are currently of 283K patients that are currently diagnosed with MF or PV in Europe and U.S..
For more ratings news on Incyte click here and for the rating history of Incyte click here.
Shares of Incyte closed at $15.08 yesterday, with a 52 week range of $6.31-$17.48.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm believes that approval from the FDA and EMEA for the drug INCB18424 is very likely. This will be the first approved drug for Myeloproliferative diseases and the next competitor is still two years behind nor does it treat many of the problems that characterize myelofibrosis (MF) and polycythemia (PV). There are currently of 283K patients that are currently diagnosed with MF or PV in Europe and U.S..
For more ratings news on Incyte click here and for the rating history of Incyte click here.
Shares of Incyte closed at $15.08 yesterday, with a 52 week range of $6.31-$17.48.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- MKM Partners Starts Pandora (P) at Sell
- Barclays Starts AT&T (T) at Equalweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
